Is ContraFect Corp. overvalued or undervalued?

Jun 25 2025 08:56 AM IST
share
Share Via
As of November 1, 2023, ContraFect Corp. is fairly valued with a P/E ratio of 15.2, a P/B ratio of 2.5, and a P/S ratio of 5.1, making it more reasonably priced compared to peers like Amgen and Gilead Sciences.
As of 1 November 2023, ContraFect Corp. has moved from overvalued to fairly valued. The company's current price-to-earnings ratio stands at 15.2, while its price-to-book ratio is 2.5, and the price-to-sales ratio is 5.1. Compared to its peers, such as Amgen with a P/E of 18.6 and Gilead Sciences at a P/B of 4.0, ContraFect appears to be more reasonably priced within its sector.

Given these ratios and the recent performance of ContraFect, which has shown a slight decline compared to the Sensex, the overall assessment indicates that the stock is fairly valued at this time.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is ContraFect Corp. technically bullish or bearish?
Jun 25 2025 08:46 AM IST
share
Share Via
Who are in the management team of ContraFect Corp.?
Jun 22 2025 10:29 PM IST
share
Share Via